Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Vivozon Pharmaceutical, a South Korean company specializing in the development and distribution of pharmaceutical drugs, is seeking to raise 250 million won ($17.2 million) as it prepares to launch ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...

A newly published study found that among drug users who experience chronic pain, daily cannabis use was linked to a higher ...

Treatment for chronic pain still relies heavily on opioids. While effective, they are highly addictive and potentially deadly ...

Beyond wanting to create more effective drugs, the motivations for constant attempts to produce new, non-opioid painkillers are largely either commercial — because opioid availability is limited ...

And the big headline here is that it’s not an opioid, and it’s non-addictive. So how does it work? Who should take it? Does it signal a new era for pain medication? Here to help break down this new ...

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...